Investigational therapies for psoriasis

被引：11

作者：

Cather, JC

Cather, JC

Abramovits, W

机构：

[1] Texas Dermatol Associates, Dallas, TX USA

[2] Baylor Univ, Med Ctr, Dallas, TX USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2003年 / 49卷 / 02期

关键词：

D O I：

10.1016/S0190-9622(03)01147-2

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

As the pathogenesis of psoriasis is better understood, specific targeted therapies are being developed. In addition to alefacept, etanercept, efaluzimab, and infliximab, discussed in separate articles in this issue, numerous other investigational therapies are currently in clinical trials, some of which will likely be approved in the future. We review the most promising of these therapies and their mechanisms of action.

引用

收藏

页码：S133 / S138

页数：6

相关论文

共 47 条

[1] CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris [J].

Abrams, JR ;

Lebwohl, MG ;

Guzzo, CA ;

Jegasothy, BV ;

Goldfarb, MT ;

Goffe, BS ;

Menter, A ;

Lowe, NJ ;

Krueger, G ;

Brown, MJ ;

Weiner, RS ;

Birkhofer, MJ ;

Warner, GL ;

Berry, KK ;

Linsley, PS ;

Krueger, JG ;

Ochs, HD ;

Kelley, SL ;

Kang, SW .

JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (09) :1243-1252

[2] Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells [J].

Abrams, JR ;

Kelley, SL ;

Hayes, E ;

Kikuchi, T ;

Brown, MJ ;

Kang, SW ;

Lebwohl, MG ;

Guzzo, CA ;

Jegasothy, BV ;

Linsley, PS ;

Krueger, JG .

JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (05) :681-693

[3] IL-10 is a key cytokine in psoriasis -: Proof of principle by IL-10 therapy:: A new therapeutic approach [J].

Asadullah, K ;

Sterry, W ;

Stephanek, K ;

Jasulaitis, D ;

Leupold, M ;

Audring, H ;

Volk, HD ;

Döcke, WD .

JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (04) :783-794

[4] Effects of systemic interleukin-10 therapy on psoriatic skin lesions:: Histologic, immunohistologic, and molecular biology findings [J].

Asadullah, K ;

Friedrich, M ;

Hanneken, S ;

Rohrbach, C ;

Audring, H ;

Vergopoulos, A ;

Ebeling, M ;

Döcke, WD ;

Volk, HD ;

Sterry, W .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2001, 116 (05) :721-727

[5] Interleukin 10 treatment of psoriasis -: Clinical results of a phase 2 trial [J].

Asadullah, K ;

Döcke, WD ;

Ebeling, M ;

Friedrich, M ;

Belbe, G ;

Audring, H ;

Volk, HD ;

Sterry, W .

ARCHIVES OF DERMATOLOGY, 1999, 135 (02) :187-192

[6]

Asadullah K, 1999, BRIT J DERMATOL, V141, P94

[7] Interleukin-10 in cutaneous disorders:: implications for its pathophysiological importance and therapeutic use [J].

Asadullah, K ;

Sabat, R ;

Wiese, A ;

Döcke, WD ;

Volk, HD ;

Sterry, W .

ARCHIVES OF DERMATOLOGICAL RESEARCH, 1999, 291 (12) :628-636

[8] Administration of DAB389IL-2 to patients with recalcitrant psoriasis:: A double-blind, phase II multicenter trial [J].

Bagel, J ;

Garland, WT ;

Breneman, D ;

Holick, M ;

Littlejohn, TW ;

Crosby, D ;

Faust, H ;

Fivenson, D ;

Nichols, J .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1998, 38 (06) :938-944

[9] Improvement in psoriasis after intradermal administration of delipidated, deglycolipidated Mycobacterium vaccae (PVAC™):: results of an open-label trial [J].

Balagon, MV ;

Tan, PL ;

Prestidge, R ;

Cellona, RV ;

Abalos, RM ;

Tan, EV ;

Walsh, GP ;

Watson, JD ;

Walsh, DS .

CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2001, 26 (03) :233-241

[10]

BARKER JNWN, 1991, AM J PATHOL, V139, P869

← 1 2 3 4 5 →